Literature DB >> 11488523

Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer.

K Fujitaka1, T Oguri, T Isobe, Y Fujiwara, N Kohno.   

Abstract

Several recent studies have demonstrated that the cytochrome p450 (CYP) family plays an important role in the metabolism of taxanes. However, the role of CYP gene expression in tumors and peripheral mononuclear cells (PMN) is unknown. We therefore investigated the levels of CYP3A4 and CYP2C gene expression using reverse transcription polymerase chain reaction (RT-PCR) in PMN from 16 previously untreated lung cancer patients to determine whether the expression of the two genes is induced by docetaxel (TXT). Neither the CYP3A4 nor the CYP2C gene was induced after administration of carboplatin (CBDCA) alone. Expression of the CYP3A4 gene was induced by the administration of TXT alone or TXT and CBDCA, but expression of the CYP2C gene was unaffected. We also measured the expression of both genes using RT-PCR in 20 autopsy samples (ten non-small-cell lung cancers and their corresponding normal lung tissues) obtained from patients who had not received any chemotherapy during life. The level of CYP2C gene expression in samples of lung cancer was significantly higher than in normal lung tissue, but the level of CYP3A4 gene expression was not. These results suggest that the CYP3A4 gene is induced by TXT, and that it plays an important role in intracellular TXT metabolism.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488523     DOI: 10.1007/s002800100291

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Cyclosporin A aerosol improves the anticancer effect of paclitaxel aerosol in mice.

Authors:  Vernon Knight; N V Koshkina; E Golunski; L E Roberts; B E Gilbert
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

2.  Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.

Authors:  M A Phelps; T E Stinchcombe; J S Blachly; W Zhao; L J Schaaf; S L Starrett; L Wei; M Poi; D Wang; A Papp; J Aimiuwu; Y Gao; J Li; G A Otterson; W J Hicks; M A Socinski; M A Villalona-Calero
Journal:  Clin Pharmacol Ther       Date:  2014-04-29       Impact factor: 6.875

3.  CYP3A4 expression to predict treatment response to docetaxel for metastasis and recurrence of primary breast cancer.

Authors:  Kenichi Sakurai; Katsuhisa Enomoto; Sadanori Matsuo; Sadao Amano; Motomi Shiono
Journal:  Surg Today       Date:  2011-05-01       Impact factor: 2.549

4.  Expression Patterns of Xenobiotic-Metabolizing Enzymes in Tumor and Adjacent Normal Mucosa Tissues among Patients with Colorectal Cancer: The ColoCare Study.

Authors:  Jolantha Beyerle; Andreana N Holowatyj; Mariam Haffa; Eva Frei; Biljana Gigic; Petra Schrotz-King; Juergen Boehm; Nina Habermann; Marie Stiborova; Dominique Scherer; Torsten Kölsch; Stephanie Skender; Nikolaus Becker; Esther Herpel; Martin Schneider; Alexis Ulrich; Peter Schirmacher; Jenny Chang-Claude; Hermann Brenner; Michael Hoffmeister; Ulrike Haug; Robert W Owen; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-18       Impact factor: 4.254

Review 5.  Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes.

Authors:  Maarten van Eijk; René J Boosman; Alfred H Schinkel; Alwin D R Huitema; Jos H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-15       Impact factor: 3.333

Review 6.  Multifunctional Role of Astrocyte Elevated Gene-1 (AEG-1) in Cancer: Focus on Drug Resistance.

Authors:  Debashri Manna; Devanand Sarkar
Journal:  Cancers (Basel)       Date:  2021-04-09       Impact factor: 6.639

7.  Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model.

Authors:  P Wonganan; W C Zamboni; S Strychor; J D Dekker; M A Croyle
Journal:  Cancer Gene Ther       Date:  2008-12-26       Impact factor: 5.987

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.